Federated Hermes Inc. Sells 5,453 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Federated Hermes Inc. decreased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 35.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,140 shares of the company’s stock after selling 5,453 shares during the period. Federated Hermes Inc.’s holdings in Prestige Consumer Healthcare were worth $698,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of PBH. Covestor Ltd increased its position in shares of Prestige Consumer Healthcare by 21.6% during the 1st quarter. Covestor Ltd now owns 834 shares of the company’s stock worth $61,000 after purchasing an additional 148 shares during the last quarter. Miller Howard Investments Inc. NY increased its holdings in Prestige Consumer Healthcare by 2.2% during the second quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock worth $534,000 after buying an additional 165 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after acquiring an additional 208 shares in the last quarter. Parallel Advisors LLC lifted its stake in Prestige Consumer Healthcare by 42.5% in the fourth quarter. Parallel Advisors LLC now owns 714 shares of the company’s stock valued at $44,000 after acquiring an additional 213 shares during the last quarter. Finally, QRG Capital Management Inc. grew its position in shares of Prestige Consumer Healthcare by 4.7% in the 2nd quarter. QRG Capital Management Inc. now owns 5,397 shares of the company’s stock valued at $372,000 after acquiring an additional 242 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analysts Set New Price Targets

Separately, DA Davidson upped their target price on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $98.75.

Prestige Consumer Healthcare Trading Down 1.2 %

Shares of Prestige Consumer Healthcare stock opened at $73.03 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90. The business has a fifty day simple moving average of $71.22 and a two-hundred day simple moving average of $69.65. Prestige Consumer Healthcare Inc. has a 1 year low of $56.34 and a 1 year high of $75.80. The company has a market capitalization of $3.63 billion, a price-to-earnings ratio of 17.51, a P/E/G ratio of 2.08 and a beta of 0.48.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 8th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.86 by $0.04. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The company had revenue of $267.10 million during the quarter, compared to analysts’ expectations of $260.54 million. During the same quarter last year, the company posted $1.06 EPS. Prestige Consumer Healthcare’s quarterly revenue was down 4.4% compared to the same quarter last year. Research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.42 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.